Skip to Content
Jump to the top of the page

Investment Banking

New Federal Funding, Electric Vehicle Growth Put the Highway Safety Services Industry in Strong Position

America’s roads and highways—in disrepair for years—are set for major improvements after an infusion of federal money and upgrades necessitated by the growing popularity of electric vehicles. That’s good news for companies that provide road and highway safety services, and for investors eyeing opportunities in what is a massive and highly fragmented market.

Key Takeaways

  • The state of the U.S. highway system and the impact of new federal funding
  • The growing popularity of electric vehicles and their effect on road improvements
  • How a focus on safety is increasing due in part to autonomous vehicles
  • What is needed to successfully navigate the local highway safety services landscape
  • Major industry participants, M&A activity, and critical investor focus areas

This is the first entry in William Blair’s series “Investing in Infrastructure Services.” If you’d like to learn more and access detailed research on market participants, accelerating investment activity in the space, and important considerations for potential investors, please contact our team or complete the form below.

Contact Us

Andy Jessen, Managing Director Co-Head of M&A
Eric Bukovac, Vice President

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • BridgeBio Pharma, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of BridgeBio Pharma, Inc. (BBIO $65.36), a commercial-stage biotech company focused on developing medicines for genetic conditions. With this initiation, senior research associate John Boyle, Ph.D. and analyst Myles Minter, Ph.D. have expanded and deepened William Blair’s existing biotechnology coverage.

    Read more
  • Labor Market Resilience: Why The “Shortage” Isn’t Slowing Down

    With real implications for investors, labor scarcity is shaping the 2026 outlook, as demographics, policy, and technology impact wages, productivity, and inflation.

    Read more
  • Jade Biosciences, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Jade Biosciences, Inc. (JBIO $14.05), a clinical-stage biotechnology company focused on developing novel biologics for the treatment of autoimmune diseases.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures